Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay L Goldstein

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|July 20, 2010
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trialFrancis K L Chan, Angel Lanas, James Scheiman, et al.
The American Journal of Gastroenterology|October 3, 2002
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidineDonald R Campbell, Marian M Haber, Eric Sheldon, et al.
Clinical Therapeutics|June 6, 2006
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 yearsJay L Goldstein, James Aisenberg, Frank Lanza, et al.
The American Journal of Gastroenterology|December 23, 2003
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United StatesJay L Goldstein, Sean Z Zhao, Thomas A Burke, et al.
Annals of Surgery|February 24, 2017
Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk Score (BEAR Score)Craig S Brown, Brittany Lapin, Jay L Goldstein, et al.
BMC Gastroenterology|July 30, 2022
Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitisEugene F Yen, Daniel B Amusin, Janet Yoo, et al.
Cardiovascular Therapeutics|January 5, 2016
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI RiskJay L Goldstein, David J Whellan, James M Scheiman, et al.
American Journal of Physiology. Cell Physiology|May 20, 2005
Expression and membrane localization of MCT isoforms along the length of the human intestineRavinder K Gill, Seema Saksena, Waddah A Alrefai, et al.
Journal of Translational Internal Medicine|July 10, 2018
Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening AlertAmoah Yeboah-Korang, Mohammad I Beig, Mohammad Q Khan, et al.
Gastrointestinal Endoscopy|May 25, 2002
Quality assessment of endoscopic ultrasoundJohn F Johanson, Greg Cooper, Glenn M Eisen, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|July 20, 2010
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trialFrancis K L Chan, Angel Lanas, James Scheiman, et al.
The American Journal of Gastroenterology|October 3, 2002
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidineDonald R Campbell, Marian M Haber, Eric Sheldon, et al.
Clinical Therapeutics|June 6, 2006
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 yearsJay L Goldstein, James Aisenberg, Frank Lanza, et al.
The American Journal of Gastroenterology|December 23, 2003
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United StatesJay L Goldstein, Sean Z Zhao, Thomas A Burke, et al.
Annals of Surgery|February 24, 2017
Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk Score (BEAR Score)Craig S Brown, Brittany Lapin, Jay L Goldstein, et al.
BMC Gastroenterology|July 30, 2022
Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitisEugene F Yen, Daniel B Amusin, Janet Yoo, et al.
Cardiovascular Therapeutics|January 5, 2016
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI RiskJay L Goldstein, David J Whellan, James M Scheiman, et al.
American Journal of Physiology. Cell Physiology|May 20, 2005
Expression and membrane localization of MCT isoforms along the length of the human intestineRavinder K Gill, Seema Saksena, Waddah A Alrefai, et al.
Journal of Translational Internal Medicine|July 10, 2018
Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening AlertAmoah Yeboah-Korang, Mohammad I Beig, Mohammad Q Khan, et al.
Gastrointestinal Endoscopy|May 25, 2002
Quality assessment of endoscopic ultrasoundJohn F Johanson, Greg Cooper, Glenn M Eisen, et al.
Pageof 7